Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cotton Rat RSV Model Launched by Noble Life Sciences and IBT Bioservices

Published: Friday, January 31, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Cotton rat model for preclinical studies of respiratory syncytial virus therapies and vaccines.

Noble Life Sciences in collaboration with IBT Bioservices has announced a newly optimized cotton rat model for preclinical studies of RSV (respiratory syncytial virus) therapies and vaccines.

The companies jointly developed the model of RSV infection in the cotton rat and demonstrated its use to evaluate the efficacy of test compounds in RSV challenge studies.

Cotton rats are the gold standard for preclinical development of drugs and vaccines for RSV. The cotton rat gained importance for RSV studies because the permissiveness of cotton rats to infection with human RSV surpasses that of mice by more than 100-fold and because the model replicates several characteristic features of the human disease.

Moreover, the predictive quality of the model is so high that treatments for severe disease advanced to clinical trials based on the results of efficacy and safety studies using cotton rats without the need for testing in primates.

Alain Cappeluti, President of Noble Life Sciences, noted, “The optimization of our RSV cotton rat model is the result of a collaborative effort combining the in vivo model expertise of Noble Life Sciences with the vaccine development and virology expertise of IBT Bioservices. Models of infection with other viral pathogens using the cotton rat will be developed. A model of influenza infection is under development in collaboration with IBT Bioservices”.

“We are pleased with our collaboration with Noble Life Sciences in the optimization of this model. Although current treatment options for prevention of RSV disease in high-risk infants are highly effective, the need for cost-effective vaccines or therapeutic options for RSV prevention and treatment in the large population of normal-risk infants and children is great. The cotton rat model of RSV infection will play a pivotal role in the development of such vaccines and therapeutics,” commented Dr. Javad Aman, President and CSO of IBT Bioservices.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Noble Life Sciences Acquires Spring Valley Laboratories
Extends testing services to GLP, large animal and medical device studies.
Thursday, December 04, 2014
Noble Life Sciences Partners with BioFactura
Partnership to offer cell line development and preclinical protein production services.
Friday, July 27, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!